A new blood test to diagnose Frontotemporal Lobar Degeneration early
Official title: A Novel Blood Test for Early Diagnosis of Frontotemporal Lobar Degeneration
Funded at Virtici, LLC · NIH-11005947 · Data updated 2026-11-12
This study is working on a new blood test to help diagnose Frontotemporal Lobar Degeneration (FTD) early and easily, so that people under 65 can get the answers they need faster and start getting the right support.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtici, LLC NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project start | August 15, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $700,000 |
| NIH project number | 1R43NS139747-01 |
| Project ID | NIH-11005947 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 45 to 64 who are experiencing symptoms of dementia or have a family history of Frontotemporal Lobar Degeneration.
✕Less likely to help
Patients who are over 65 or do not exhibit symptoms of dementia may not benefit from this research.
What this research studies
This research aims to create a blood test that can diagnose Frontotemporal Lobar Degeneration (FTD) early and accurately. FTD is a type of dementia that primarily affects individuals under 65, and current diagnostic methods are lengthy and complex, often taking years. By analyzing specific protein markers found in the blood, the researchers hope to simplify the diagnostic process, making it quicker and more accessible for patients. This approach could significantly reduce the time it takes to receive a diagnosis and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of Frontotemporal Lobar Degeneration, allowing for timely interventions and better management of the condition.
How similar studies have gone: Previous research has shown promise in using blood tests to detect Alzheimer's Disease, indicating that a similar approach for FTD could be successful.
Where this research is happening
-
Virtici, LLC
Seattle, United States Active
Researchers
- Principal investigator: Fanger, Neil a — Virtici, LLC
- Study coordinator: Fanger, Neil a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.